Skip to main content
No.1 Press Release Service in Korea
Search
Search
Login
Create Account
Services
Contact Us
News
Services
About Us
Contact Us
Korean
News
All News
News by Region
Korea
Overseas
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Services
Why Korea Newswire?
How We Distribute
Services & Pricing
Basic
Standard
Premium
Global
Translation
Press Release Network in Korea
Korean Language
About Us
News
Services
Contact Us
Search
Cancel
Search
Submit Press Release
Latest News
News by Region
Korea
World
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Health News Releases
Today April 20
January 17, 2024 15:57
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral
January 17, 2024 15:55
Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference
On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 C
January 17, 2024 15:30
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufa
January 17, 2024 15:05
Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index. W
January 17, 2024 15:05
Parse Biosciences Acquires Biomage
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53882475&newsitemid=20240116719945&lan=en-US&anchor=Parse+Biosciences&index=1&md
January 17, 2024 14:33
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53882479&newsitemid=20240115984065&lan=en-US&anchor=TSE%3A4502%2FNYSE%
January 16, 2024 09:40
Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FD
January 12, 2024 17:40
ELIQUENT Life Sciences Announces Steve Purtell as Chief Financial Officer
ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of Steve Purtell as its new chief financial officer (CFO). This strategic ad
January 12, 2024 10:20
QPS Significantly Enhances Mass Spectrometry Laboratory Capacity
QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass
January 11, 2024 09:45
Medidata Secures Top Honors in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® Assessment
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Medidata&index=1&md5=f2d573b2db328d38013
January 10, 2024 16:22
Kolmar BNH’s HemoHIM gets dual recognition for fatigue improvement, immune enhancement
Kolmar BNH, a Korean health supplement original development manufacturing (ODM), said the Ministry of Food and Drug Safety has recognized both fatigue improvement and immune enhancement capabilities f
January 10, 2024 15:10
World’s First Kidney Tumor Treated Using the HistoSonics’ Edison® Histotripsy System
HistoSonics, Inc., (www.histosonics.com), developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the treatment of the first patient in its pivotal #HOPE4
January 10, 2024 13:20
Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves
Neuraptive Therapeutics, Inc., a leader in nerve repair and regeneration, is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries. The succe
January 10, 2024 10:10
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into
January 09, 2024 15:15
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of
January 09, 2024 14:00
Validant Group of Companies Unite as ELIQUENT Life Sciences
The Validant Group of companies today announced a strategic repositioning that unites the five companies as one global regulatory brand: ELIQUENT Life Sciences. ELIQUENT Life Sciences is the fusion
January 07, 2024 12:54
World’s First Patients Treated With Novel Edison® Histotripsy System
HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester Medical Center has received the world’s
January 07, 2024 11:23
Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023
January 05, 2024 11:15
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthca
January 05, 2024 10:30
Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine tran
December 29, 2023 09:30
Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. Th
December 28, 2023 14:30
CCM Biosciences Announces Launch of 5Prime Sciences Business Unit
Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com
December 22, 2023 13:59
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=53874021&newsitemid=20231221976317&lan=en-US&anchor=TSE%3A4
December 21, 2023 10:15
Biocytogen Enters into Multi-Target Antibody Agreement With Neurocrine Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc. The ag
December 20, 2023 11:25
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced an agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine
«
17
18
19
20
21
»
25 per page
25 per page
50 per page
75 per page
100 per page
Distribute Your News to
KOREA
The largest press release distribution network in Korea
34,000 journalists
7,000 media outlets
345 industry channel
80,000 subscribers
Get Started
Global PR service
Reach Your Target
Audience in 160 Countries
powered by
Get Started
News by region
Korea
Overseas
News by industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Notice